Response to pazopanib‐based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma
Abstract Angiogenesis inhibitors (AGI) are not presently used for the treatment of gastric cancers. This report demonstrates that angiogenesis inhibitor can be safely and effectively used in combination with cytotoxic anti‐cancer agents for treatment of Gastric cancers.
Guardado en:
Autores principales: | Sewanti Limaye, Darshana Patil, Dadasaheb Akolkar, Navin Srivastava, Revati Patil, Sachin Apurwa, Sanket Patil, Jinumary John, Rahul Gosavi, Prabhu Nesargikar, Prashant Kumar, Vineet Datta, Chirantan Bose, Zarrine Raazi, Ajay Srinivasan, Rajan Datar |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/65674c3e054d4917ac8f5a42efa27c35 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
por: Eijiro Shimada, et al.
Publicado: (2021) -
Prolonged Survival Using First-Line Pazopanib in a Filipino Male with Renal Cell Carcinoma and Brain Metastasis: A Case Report
por: Christianne V. Mojica, et al.
Publicado: (2021) -
Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma
por: Laura Molenaar-Kuijsten, et al.
Publicado: (2021) -
Simondon reconsidered
por: Enrico Monacelli, et al.
Publicado: (2021) -
Pazopanib for the treatment of soft-tissue sarcoma
por: Heudel P, et al.
Publicado: (2012)